Low-dose CAR-T cells group — Competitive Intelligence Brief

Low-dose CAR-T cells group (Low-dose CAR-T cells group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CAR-T cell therapy. Area: Oncology.

phase 3 CAR-T cell therapy Tumor-associated antigens (specific target antigen not specified) Oncology Biologic

Target snapshot

Low-dose CAR-T cells group (Low-dose CAR-T cells group) — Guangzhou Women and Children's Medical Center. Low-dose CAR-T cells are engineered T lymphocytes expressing chimeric antigen receptors at reduced cell doses to target and kill cancer cells while potentially reducing toxicity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Low-dose CAR-T cells group TARGET	Low-dose CAR-T cells group	Guangzhou Women and Children's Medical Center	phase 3	CAR-T cell therapy	Tumor-associated antigens (specific target antigen not specified)
cART	cART	LI Taisheng	marketed	CAR-T cell therapy	Tumor-associated antigen (specific target depends on formulation)
Relma-cel	Relma-cel	Shanghai Ming Ju Biotechnology Co., Ltd.	marketed	CAR-T cell therapy
IL-7/IL-15 pre-treated CD19 cells	IL-7/IL-15 pre-treated CD19 cells	jiangjingting	marketed	CAR-T cell therapy	CD19
BMS-986353	BMS-986353	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	phase 3	CAR-T cell therapy	Tumor-associated antigen (specific target not publicly disclosed in detail)
SCTV01E	SCTV01E	Sinocelltech Ltd.	phase 3	CAR-T cell therapy
BMS-986393	BMS-986393	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	phase 3	CAR-T cell therapy	CD19

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CAR-T cell therapy class)

1. Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · 3 drugs in this class
2. Chongqing Precision Biotech Co., Ltd · 2 drugs in this class
3. Guangzhou Women and Children's Medical Center · 2 drugs in this class
4. Sinocelltech Ltd. · 2 drugs in this class
5. Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 drug in this class
6. Guangzhou Bio-gene Technology Co., Ltd · 1 drug in this class
7. Celyad Oncology SA · 1 drug in this class
8. Janssen Scientific Affairs, LLC · 1 drug in this class
9. EdiGene Inc. · 1 drug in this class
10. Hrain Biotechnology Co., Ltd. · 1 drug in this class